The logic is incremental. Semaglutide (single, GLP-1) produced ~15% weight loss in obesity trials. Tirzepatide (dual, GIP + GLP-1) produced ~21%. Each additional receptor added metabolic effects the previous level couldn't produce. The question driving triple agonism research: does adding glucagon receptor activation to dual GIP/GLP-1 agonism produce yet another increment?

The Phase 2 data says yes. Retatrutide, the first triple GIP/GLP-1/glucagon agonist tested in clinical trials, produced 24.2% mean body weight reduction at the highest dose over 48 weeks — the largest reduction reported in any anti-obesity drug trial at the time of publication.¹

But the raw numbers don't explain what glucagon adds. Understanding that requires examining what the glucagon receptor does that GIP and GLP-1 receptors don't.

Glucagon has been metabolic medicine's paradox for decades. It raises blood glucose (counterproductive for diabetes treatment), yet it also increases energy expenditure and promotes hepatic fat oxidation (potentially useful for metabolic health). For years, pharmacologists avoided glucagon agonism because the glucose-raising effect seemed to outweigh the benefits.

Triple agonism resolves this paradox by buffering glucagon's glucose-raising effect with GLP-1's glucose-lowering effect. The two receptors counterbalance each other on glucose, while glucagon's unique contributions — thermogenesis and liver fat clearance — add new metabolic effects on top of the dual-agonist platform.²

What glucagon specifically adds:

Hepatic fat oxidation. Glucagon receptor activation in the liver promotes fatty acid oxidation in hepatocytes — the liver literally burns more fat. This is absent from GLP-1 and GIP agonism and is particularly relevant to non-alcoholic fatty liver disease (NAFLD/NASH) research, where hepatic fat accumulation is the primary pathology.³

Increased energy expenditure. Glucagon increases resting metabolic rate through thermogenesis — the generation of heat from metabolic processes. This means triple agonism potentially reduces caloric intake (GLP-1 + GIP appetite effects) while simultaneously increasing caloric expenditure (glucagon thermogenesis). The combination addresses both sides of the energy balance equation.

Body composition effects. Preclinical data suggests that the glucagon component may help preserve lean mass during weight loss — a significant concern because rapid weight loss from any intervention typically includes lean tissue loss alongside fat loss.

The NEJM-published Phase 2 trial of retatrutide provides the most direct evidence for triple agonism benefits. Key findings at 48 weeks with the highest dose:⁴

• Mean body weight reduction: 24.2% (vs 2.1% placebo)
• 26% of participants achieved ≥30% body weight reduction
• Dose-dependent efficacy across all dose levels tested
• Side effect profile broadly consistent with the incretin class (GI effects most common)
• Reductions in liver fat measured by MRI (relevant to the glucagon hepatic component)

The weight loss magnitude exceeded both semaglutide STEP data (~15%) and tirzepatide SURMOUNT data (~21%), supporting the incremental receptor targeting hypothesis.

The OSYRIS catalog uniquely enables the complete single → dual → triple comparison:

Each step adds ~3-6 percentage points of incremental weight loss, along with qualitatively new metabolic effects (GIP: adipose signaling; Glucagon: hepatic fat, thermogenesis). Researchers can use all three in preclinical models to isolate each receptor's contribution.

Phase 2 only. Retatrutide has not completed Phase 3 trials. Sample sizes are smaller than Phase 3 programs, and long-term outcomes (>48 weeks) are not available.

Glucagon glucose effects. While the glucose-raising effect appears buffered by GLP-1 in healthy/obese individuals, the balance in diabetes populations with impaired insulin secretion requires further study.

Ceiling question. Is triple the ceiling, or would a quadruple agonist (adding amylin, for example, via cagrilinitide co-administration) produce further benefits? The CagriSema + glucagon concept has not been tested.

Long-term safety. Multi-year cardiovascular outcome data does not exist for triple agonists. GLP-1 agonists have demonstrated cardiovascular benefits in long-term trials — whether triple agonism preserves or enhances these benefits is unknown.⁵